GLP-1 receptor agonists show promising neuroprotective effects in preclinical models of Alzheimer's and Parkinson's disease, with early clinical trials showing motor benefits in Parkinson's and intriguing brain metabolism preservation in Alzheimer's, though definitive evidence awaits large Phase 3 trials.
EVOKE trials will be definitiveLarge Phase 3 trials (EVOKE and EVOKE+) testing semaglutide for Alzheimer's disease will determine whether GLP-1 drugs can become the first metabolic pathway-based disease-modifying treatment for neurodegeneration.
What the researchers found
Preclinical: GLP-1RAs reduce neuroinflammation, improve mitochondrial function, and enhance clearance of toxic proteins in both AD and PD models, leading to improved cognition and dopaminergic neuron survival.
Clinical — Parkinson's: Exenatide and lixisenatide demonstrated motor benefits in trials. However, NLY01 (pegylated exendin) did not meet its primary endpoint, showing not all GLP-1RAs perform equally.
Clinical — Alzheimer's: Mixed cognitive outcomes in early trials, but liraglutide preserved cerebral glucose metabolism on FDG-PET scans — an intriguing biological effect suggesting neuroprotection even without clear cognitive benefit.
The EVOKE and EVOKE+ Phase 3 trials with semaglutide are the definitive tests that could establish GLP-1RAs as neurodegenerative disease treatments.
Why it matters
Alzheimer's and Parkinson's diseases affect tens of millions globally with limited treatment options. Finding that GLP-1 drugs — already proven safe in millions of diabetes and obesity patients — could modify neurodegenerative disease course would be transformative. The existing safety and manufacturing infrastructure means these drugs could be rapidly deployed if efficacy is confirmed, unlike entirely new drug candidates that require years of development.
How the study worked
Narrative review of preclinical evidence (animal models of AD and PD), early clinical trial results, and ongoing clinical trials for GLP-1 receptor agonists in neurodegenerative diseases. The review covers endocrine pathways, CNS mechanisms, and clinical evidence across multiple GLP-1RA agents.
What this study cannot tell us
This is a narrative review, not a systematic review. Preclinical promise has often failed to translate to clinical benefit in neurodegeneration (the 'translational gap'). Early AD clinical trials have had mixed cognitive results. Not all GLP-1RAs appear equally effective (NLY01 failed in PD). Brain penetration varies between GLP-1RAs, which may explain different outcomes. The EVOKE trials have not yet reported results. Long-term CNS effects of chronic GLP-1RA use are unknown.
How to read the evidence
This is a narrative review covering preclinical studies and early-phase clinical trials. The preclinical evidence is consistent and promising, but human evidence is preliminary and mixed. Definitive Phase 3 trial data (EVOKE) are not yet available.
When this study was published
Published in 2025, this review captures the latest preclinical and clinical evidence, including the most recent trial results and ongoing Phase 3 programs, representing the current frontier of GLP-1RA neuroscience.
The bigger picture
The potential of GLP-1 drugs for neurodegeneration is perhaps the most exciting frontier in the GLP-1 revolution. The biological rationale is strong: insulin resistance, neuroinflammation, and impaired energy metabolism are all implicated in both AD and PD, and GLP-1RAs address all three. If the EVOKE trials succeed, semaglutide could become the first disease-modifying drug for Alzheimer's disease proven in a large RCT that works through metabolic/inflammatory pathways rather than amyloid clearance — a paradigm shift in the field.
Questions still open
- Will the EVOKE trials with semaglutide demonstrate cognitive benefits in Alzheimer's disease?
- Does brain penetration of different GLP-1RAs explain the varying neurological trial results?
- Could earlier intervention with GLP-1RAs (before significant neurodegeneration) show greater neuroprotective benefit?
Common questions
Could semaglutide or other GLP-1 drugs prevent Alzheimer's disease?
Why might diabetes drugs help with brain diseases?
Read the original research
GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.
Frontiers in endocrinology, 16, 1708565
Citation
Gandhi, Ayush; Parhizgar, Alireza. (2025). GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.. Frontiers in endocrinology, 16, 1708565. https://doi.org/10.3389/fendo.2025.1708565